Area of research
Oncology · Immunology
Research interest
Research focused on Lung cancer and Inflammasome, with related work in Cancer research, Gene knockdown, Tolerability. Notable publications include 'Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors', 'Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis', and 'Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review'.
LncRNA MIR503HG regulates NETs‐mediated NLRP3 inflammasome activation and NSCLC metastasis by enhancing the ubiquitination of C/EBPβ
High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody–drug conjugate targeting Trop-2 is a promising therapeutic approach
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review
CDC23 knockdown suppresses the proliferation, migration and invasion of liver cancer via the EMT process
Survival Predictors of Resectable Gallbladder Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database
rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis